18.07.2007 18:34:00
|
Pfizer Announces First Occupant in its Science Incubator
Pfizer today announced its first occupant for the company’s
Incubator – a new development where scientific
entrepreneurs progress their ideas towards innovative treatments for
serious diseases.
Vaughn Smider MD, PhD, an assistant professor at The Scripps Research
Institute, in La Jolla CA, will work to develop a unique technology to
identify antibodies that might lead to new therapies. He will build his
new company, Fabrus LLC at the Incubator, located at Pfizer’s
Research & Development site in La Jolla.
"We’ve had a really
warm reception from the biotech community and academic scientists, said
Pfizer’s Alex Polinsky, who heads the
Incubator. "We are helping to fill the need
for support and funding for early scientific work. The Incubator is a
channel that brings innovation one step closer to patients. If
successfully developed, Fabrus technology could lead to new therapies in
many therapeutic areas.”
In total, Pfizer will invest $10 million a year to support life science
start-ups based in the incubator. Pfizer continues to review research
proposals and expects other occupants to move to the facility in the
near future.
Fabrus plans eventually to employ six - eight scientists, who will have
laboratory and office space in part of the new incubator facility.
Fabrus will receive Pfizer support for two years. At the end of the
term, Pfizer has an option to acquire the company and its technologies,
or Fabrus may spin out as an independent enterprise.
"The Incubator allows me to focus on science,”
said Dr Smider. "We won’t
have to devote time to business complexities, like funding, equipment
purchase and payroll. We also benefit from our proximity to Pfizer and
its considerable scientific resources.”
During the two-year incubation period, Fabrus will work to develop novel
antibody libraries, and ways to screen them against biological targets.
The technology will be tested on targets in some of Pfizer’s
11 disease areas.
About The Pfizer Incubator
The Pfizer Incubator (TPI) offers scientist-entrepreneurs an opportunity
to bring their medical innovations to patients. In TPI,
scientist-entrepreneurs contribute innovative ideas and the ability to
solve complex scientific and technical challenges, while TPI provides
all necessary resources to move ideas forward into practice.
More details are at: www.thepfizerincubator.com
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
JETZT DEVISEN-CFDS MIT BIS ZU HEBEL 30 HANDELN
Handeln Sie Devisen-CFDs mit kleinen Spreads. Mit nur 100 € können Sie mit der Wirkung von 3.000 Euro Kapital handeln.
82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren.
Nachrichten zu Pfizer Inc.mehr Nachrichten
Analysen zu Pfizer Inc.mehr Analysen
14.11.24 | Pfizer Neutral | UBS AG | |
01.11.24 | Pfizer Neutral | UBS AG | |
30.10.24 | Pfizer Buy | Goldman Sachs Group Inc. | |
29.10.24 | Pfizer Buy | Jefferies & Company Inc. | |
24.10.24 | Pfizer Neutral | JP Morgan Chase & Co. |
Aktien in diesem Artikel
Pfizer Inc. | 24,57 | 0,74% |
Indizes in diesem Artikel
Dow Jones | 44 722,06 | -0,31% | |
S&P 500 | 5 998,74 | -0,38% | |
S&P 100 | 2 883,15 | -0,41% | |
NYSE US 100 | 17 376,20 | -0,02% |